Skip to Content

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

Pemigatinib – a oral FGFR1-3 inhibitor has shown efficacy and safety in patients with advanced/metastatic cholangiocarcinoma publish in the Lancet Oncol 2020. In this MEDtalk Abou-Alfa K. Ghassan present the update FIGHT-202 study, where overall survival for responders was more than twice as long vs for non-responders

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top